John E. Connolly is the Program Coordinator for Technology and Translation at A*STAR’s Institute of Molecular and Cell Biology (IMCB). Connolly joined A*STAR’s Singapore Immunology Network (SIgN) in 2010, where he ran the immunomonitoring platform, before moving to IMCB in 2013. Connolly’s group at IMCB explores broad topics in translational immunology, including human studies in dendritic cell biology, immunometabolism, primary immunodeficiency, and immunomonitoring of clinical infectious disease cohorts. From 2011, he has been a Director of ASPIRE, the A*STAR Programme in Translational Research on Infectious Disease. He has also held concurrent appointments as Chief Scientific Officer at Tessa Therapeutics in Singapore from 2017 to 2020, and now as Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy in San Francisco, CA.
